PepGen (PEPG) Stock Price, News & Analysis

Company Overview

PepGen, Inc. (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome). These in vivo gene editing candidates are engineered to restore enzyme activity in affected tissues, potentially reducing the burden of repeated interventions. Beyond lysosomal storage disorders, PepGen is advancing earlier-stage research in inherited cardiovascular and metabolic conditions leveraging the same platform.

Founded in 2020 by a cohort of genome engineering scientists, PepGen has assembled an interdisciplinary team with expertise in translational research, clinical development and regulatory strategy. The company’s research operations are based in San Diego, where it maintains research laboratories and manufacturing collaborations. PepGen also partners with academic institutions and clinical centers across the United States to support preclinical studies and future clinical trial sites.

Under the leadership of Chief Executive Officer David Becker, who previously held senior roles at multiple biotechnology firms, PepGen is preparing its pipeline for regulatory interactions and human trials. The company has initiated strategic alliances to extend its capabilities in vector production and to explore commercialization pathways in North America and Europe.

Key Stats

• Today's Range: $2.11 to $2.28
• 50-Day Range: $1.35 to $2.44
• 52-Week Range: $1.01 to $7.80
• Volume: 578,008 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $146.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Moderate Buy

PepGen Stock Analysis - MarketRank™

PepGen scored higher than 53% of companies evaluated by MarketBeat, and ranked 1277th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PepGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PepGen has a consensus price target of $11.50, representing about 442.5% upside from its current price of $2.12.

Amount of Analyst Coverage

PepGen has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PepGen are expected to decrease in the coming year, from ($1.20) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PepGen is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PepGen is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PepGen has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.86% of the float of PepGen has been sold short.

Short Interest Ratio / Days to Cover

PepGen has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in PepGen has recently increased by 3.83%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PepGen does not currently pay a dividend.

Dividend Growth

PepGen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

PepGen has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for PepGen this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for PEPG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,739.00 in company stock.

Percentage Held by Insiders

1.30% of the stock of PepGen is held by insiders.

Percentage Held by Institutions

58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/22/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PEPG
• CIK: 1835597
• Web: www.pepgen.com
• Phone: 781-797-0979
• Fax: N/A
• Employees: 30
• Year Founded: 2018

Price Target and Rating

• Average Price Target for PepGen: $11.50
• High Price Target: $20.00
• Low Price Target: $4.00
• Potential Upside/Downside: +442.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -59.89%
• Return on Assets: -49.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.98
• Quick Ratio: 14.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 0.99

Miscellaneous

• Outstanding Shares: 69,170,000
• Free Float: 68,270,000
• Market Cap: $146.64 million
• Optionable: Not Optionable
• Beta: 1.88